Catalyst Biosciences Receives US Patent for its Anti-Complement Factor 3 Portfolio of Engineered Proteases
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the United States Patent and Trademark Office (USPTO) has issued US Patent Number 10,781,435 B2 entitled “Modified Membrane Type Serine Protease 1 (MTSP-1) Polypeptides and Methods of Use.” This patent covers Catalyst’s portfolio of engineered proteases that selectively cleave and degrade complement factor 3 (C3), including the lead candidate CB 2782-PEG, a potential best-in-class treatment for dry AMD currently partnered with Biogen. These modified proteases inhibit complement activation and have the potential to treat multiple diseases in which dysregulated complement activation plays a role. The newly issued patent provides protection until at least 2038.
“CB 2782 demonstrates the power of our protease engineering platform and focus on the complement cascade. We plan to leverage our platform to expand the number of candidates we move into clinical development over the coming years,” said Nassim Usman, Ph.D., president and chief executive officer of Catalyst Biosciences.
About Catalyst Biosciences